International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.14214053
Original Research Article
10% Lignocaine Spray Versus Eutectic Mixture of 2.5% Lignocaine With 2.5% Prilocaine for Attenuating Venous Cannulation Pain in Adults: A Clinical Comparitive Study
Published
Nov. 25, 2024
Abstract

Background: Venous cannulation is a common yet painful procedure in healthcare settings. This study aimed to compare the efficacy of 10% Lignocaine spray with EMLA cream for pain attenuation during venous cannulation in adults.Methods: A prospective, randomized, comparative study was conducted on 88 adult patients undergoing elective surgeries. Patients were randomly allocated to receive either 10% Lignocaine spray (n=44) or EMLA cream (n=44) prior to venous cannulation. Pain scores were assessed using a visual analog scale (VAS), and hemodynamic parameters were recorded before and after the procedure.Results: The mean pain scores were 2.98 ± 1.45 for the Lignocaine spray group and 3.22 ± 1.38 for the EMLA cream group (p = 0.4287), indicating no significant difference in analgesic efficacy. Hemodynamic parameters, including heart rate, blood pressure, and mean arterial pressure, showed no significant differences between the groups at any time point (p > 0.05 for all comparisons).Conclusion: 10% Lignocaine spray demonstrated comparable efficacy to EMLA cream in reducing venous cannulation pain, with the advantage of a significantly shorter application time. Both methods maintained similar hemodynamic stability and safety profiles.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
58 Views
203 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved